Get started
TG THERAPEUTICS INC COM USD0.001TG THERAPEUTICS INC COM USD0.001TG THERAPEUTICS INC COM USD0.001

TG THERAPEUTICS INC COM USD0.001

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

0VGI chart


Full chart

0VGI upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪6.26 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
276.145
Basic EPS (TTM)
0.160 USD
Net income (FY)
‪23.38 M‬ USD
Revenue (FY)
‪329.00 M‬ USD
Shares float
‪141.43 M‬
Beta (1Y)
0.87

Employees


Employees (FY)
338
Change (1Y)
+74 +28.03%
Revenue / Employee (1Y)
‪973.38 K‬ USD
Net income / Employee (1Y)
‪69.18 K‬ USD

About TG Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Michael Sean Weiss
Website
tgtherapeutics.com
Headquarters
Morrisville
Founded
1993
FIGI
BBG00LJZ6D55
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

0VGI news



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Check out other big names from the same industry as 0VGI.

Frequently Asked Questions


The current price of 0VGI is 37.500 USD — it has decreased by −2.72% in the past 24 hours. Watch TG THERAPEUTICS INC COM USD0.001 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange TG THERAPEUTICS INC COM USD0.001 stocks are traded under the ticker 0VGI.
0VGI stock has fallen by −2.72% compared to the previous week, the month change is a 12.50% rise, over the last year TG THERAPEUTICS INC COM USD0.001 has showed a 147.52% increase.
We've gathered analysts' opinions on TG THERAPEUTICS INC COM USD0.001 future price: according to them, 0VGI price has a max estimate of 55.00 USD and a min estimate of 10.00 USD. Watch 0VGI chart and read a more detailed TG THERAPEUTICS INC COM USD0.001 stock forecast: see what analysts think of TG THERAPEUTICS INC COM USD0.001 and suggest that you do with its stocks.
0VGI reached its all-time high on Jan 13, 2021 with the price of 56.310 USD, and its all-time low was 3.565 USD and was reached on Jun 16, 2022. View more price dynamics on 0VGI chart.
See other stocks reaching their highest and lowest prices.
0VGI stock is 2.80% volatile and has beta coefficient of 0.87. Track TG THERAPEUTICS INC COM USD0.001 stock price on the chart and check out the list of the most volatile stocks — is TG THERAPEUTICS INC COM USD0.001 there?
Today TG THERAPEUTICS INC COM USD0.001 has the market capitalization of ‪6.26 B‬, it has decreased by −3.59% over the last week.
Yes, you can track TG THERAPEUTICS INC COM USD0.001 financials in yearly and quarterly reports right on TradingView.
TG THERAPEUTICS INC COM USD0.001 is going to release the next earnings report on May 6, 2025. Keep track of upcoming events with our Earnings Calendar.
0VGI earnings for the last quarter are 0.15 USD per share, whereas the estimation was 0.16 USD resulting in a −4.55% surprise. The estimated earnings for the next quarter are 0.16 USD per share. See more details about TG THERAPEUTICS INC COM USD0.001 earnings.
TG THERAPEUTICS INC COM USD0.001 revenue for the last quarter amounts to ‪108.19 M‬ USD, despite the estimated figure of ‪100.67 M‬ USD. In the next quarter, revenue is expected to reach ‪117.13 M‬ USD.
0VGI net income for the last quarter is ‪23.33 M‬ USD, while the quarter before that showed ‪3.88 M‬ USD of net income which accounts for 501.29% change. Track more TG THERAPEUTICS INC COM USD0.001 financial stats to get the full picture.
No, 0VGI doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 1, 2025, the company has 338 employees. See our rating of the largest employees — is TG THERAPEUTICS INC COM USD0.001 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TG THERAPEUTICS INC COM USD0.001 EBITDA is ‪42.21 M‬ USD, and current EBITDA margin is 12.83%. See more stats in TG THERAPEUTICS INC COM USD0.001 financial statements.
Like other stocks, 0VGI shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TG THERAPEUTICS INC COM USD0.001 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TG THERAPEUTICS INC COM USD0.001 technincal analysis shows the buy rating today, and its 1 week rating is strong buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TG THERAPEUTICS INC COM USD0.001 stock shows the strong buy signal. See more of TG THERAPEUTICS INC COM USD0.001 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.